Free Trial
TSE:BHC

Bausch Health Companies 11/2/2023 Earnings Report

Bausch Health Companies logo
C$10.16 +0.33 (+3.36%)
As of 08/29/2025 04:00 PM Eastern

Bausch Health Companies EPS Results

Actual EPS
C$1.38
Consensus EPS
C$1.23
Beat/Miss
Beat by +C$0.15
One Year Ago EPS
N/A

Bausch Health Companies Revenue Results

Actual Revenue
$3.00 billion
Expected Revenue
$2.96 billion
Beat/Miss
Beat by +$42.48 million
YoY Revenue Growth
N/A

Bausch Health Companies Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Bausch Health Companies Earnings Headlines

Analysts Offer Predictions for TSE:BHC FY2025 Earnings
Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why
Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight.tc pixel
Bausch Health Companies Inc. (BHC) Stock forecasts
Bausch Health stock soars after Paulson increases stake
See More Bausch Health Companies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bausch Health Companies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bausch Health Companies and other key companies, straight to your email.

About Bausch Health Companies

Bausch Health Companies (TSE:BHC) operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

View Bausch Health Companies Profile

More Earnings Resources from MarketBeat